Pharmacotherapy for systolic dysfunction: A review of randomized clinical trials

American Journal of Cardiology

Volumn 80, Issue 8 B, 1997, Pages

  Gheorghiade, Mihai ^a   Benatar, Daniel ^b   Konstam, Marvin A ^c   Stoukides, Cheryl A ^d   Bonow, Robert O ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d Medical Outcomes Management Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; CARVEDILOL; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENOXIMONE; FELODIPINE; FLOSEQUINAN; HYDRALAZINE; IBOPAMINE; LOSARTAN; METOPROLOL; MILRINONE; PIMOBENDAN; PIPERANOMETOZINE; PROSTACYCLIN; RAMIPRIL; SOTALOL; TRANDOLAPRIL; VASODILATOR AGENT; XAMOTEROL;

CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DISEASE COURSE; DRUG MECHANISM; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TREATMENT PLANNING;

EID: 0030784454     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00816-3     Document Type: Conference Paper

References (73)

1. American Heart Association. Heart and stroke facts: 1996 statistical supplement, p.15.
2. Yamani M, Massie BM. Congestive heart failure insights from epidemiology, implications for treatment . Mayo Clin Proc. 68:1993;1214-1218.
3. Eriksson H. Heart failure a growing public health problem . J intern Med. 237:1995;135-141.
4. Clinical Practice Guidelines. Heart failure: evaluation and care of patients with left ventricular systolic dysfunction. AHCPR Publication No. 940612. June 1994,11-23.
5. Williams JF Jr, Bristow MR, Fowler MB, Francis GS, Garson A, Gersh BJ, Hammer DF, Klatky MA, Leier CV, Packer M, Pitt B, Ullyot DJ, Wexler LF, Winters WL. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). J Am Coll Cardiol. 26:1995;1376-1398.
6. CDC. Mortality from Congestive Heart Failure - United States, 1980-1990. MMWR 1994;5:77-81.
7. Kannel WB, Ho K, Thom T. Changing epidemiological features of cardiac failure. Am Heart J. 72:(suppl):1994;S3-S9.
8. Ho KKL, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure the Framingham Study . J Am Coll Cardiol. 22:(suppl A):1993;6A-13A.
9. Ho KKL, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 88:1993;107-115.
10. Garg R, Packer M, Pitt B, Yusuf S. Heart failure in the 1990s. Evolution of a major public health problem in cardiovascular medicine. J Am Coll Cardiol. 22:(suppl A):1993;3A-5A.
11. Chakko S, Woska D, Martinez H, de Marchena E, Futterman L, Kessler KM, Myerberg RJ. Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure conflicting results may lead to inappropriate care . Am J Med. 90:1991;353-359.
12. Chakko S, Gheorghiade M. Estimating severity of chronic heart failure a clinical challenge for the 1990s . Am Heart J. 124:1992;260-264.
13. Bourassa MG, Gurne O, Bangdiwala SI, Ghali JK, Young JB, Rousseau M, Johnstone DE, Yusuf S. Natural history and patterns of current practice in heart failure. J Am Coll Cardiol. 22:(suppl A):1993;14A-19A.
14. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure an epidemiologic perspective . J Am Coll Cardiol. 26:1995;1565-1574.
15. Schocken DD, Arrieta MI, Leaverton PE. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol. 20:1992;301-306.
16. Stevenson WG, Stevenson LW, Middlekauff HR, Saxon LA. Sudden death prevention in patients with advanced ventricular dysfunction. Circulation. 88:1993;2953-2961.
17. Effects of enalapril on mortality in severe congestive heart failure results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) . N Engl J Med. 316:1987;1429-1435.
18. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 325:1991;293-302.
19. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 327:1992;685-691.
20. Yusef S, Pepine CJ, Garces C, Pouler H, Salem D, Kostis J, Benedict C, Rousseau M, Bourassa M, Pitt B. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet. 340:1992;1173-1178.
21. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristanti F, Smith R, Dunkman WB, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes CV, Carson P, Cintron G, Shabetai R, Haakenson C. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 325:1991;303-310.
22. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristanti FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, Goldman S, Cobb FR, Shah PM, Saunders R, Fletcher RD, Loeb HS, Hughes VC, Baker B. Effect of vasodilator therapy on mortality in chronic congestive heart failure results of a Veterans Administration Cooperative Study . N Engl J Med. 314:1986;1547-1552.
23. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr. , Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med. 327:1992;669-677.
24. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 342:1993;821-828.
25. Kobel L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliason P, Lynborg K, Bideabaek J, Cole DS, Auclert L, Pauly NC, Aliot E, Persson S, Camm AJ. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 333:1995;1670-1676.
26. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania DC, Ney DE, Snavely DB, Chang PI. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 349:1997;747-752.
27. Pitt B. Use of 'Xapril' in patients with chronic heart failure. A paradigm or epitaph for our times? Circulation. 90:1994;1550-1551.
28. Roden RL. Cardiovascular News Cardiovascular and renal advisory panel of the United States Food and Drug Administration consider 4 drugs . Circulation. 95:1997;2335-2337.
29. Sueta CA, Gheorghiade M, Adams KF, Bourge RC, Murali S, Uretsky BF, Pritzker MR, McGoon MD, Butman SM, Grossman SH, Crow JW, Shaffer CL, Thorn MD. Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Am J Cardiol. 75:1995;34A-43A.
30. Califf RM, Adams KF, McKenna WJ, Gheorghiade M, Uretsky BF, McNulty SE, Darius H, Schulman K, Zannad F, Handberg-Thurmond E, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure the Flolan International Randomized Survival Trial (FIRST) . Am Heart J. 134:1997;44-54.
31. Bonow RO, Galié N, Gheorghiade M, Magnani B. Prostacyclin basic principles and clinical application in congestive heart failure and primary pulmonary hypertension . Am J Cardiol. 75(Suppl):1995;1A-73A.
32. Packer M, Rouleau J, Swedberg K, Pitt B, Fisher L, Klepper M. Effect of flosequinan on survival in chronic heart failure Preliminary results of the PROFILE study . (Abstr.) Circulation. 88:1993;I-501.
33. Packer M, Narahara KA, Elkayam U, Sullivan JM, Pearle DL, Massie BM, Creager MA. Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study. J Am Coll Cardiol. 22:1993;65-72.
34. Packer M. The neurohormonal hypothesis a theory to explain the mechanism of disease progression in heart failure . [Editorial.] J Am Coll Cardiol. 20:1992;248-254.
35. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmorson A. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 342:1993;1441-1446.
36. A randomized trial of blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation. 90:1994;1765-1773.
37. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 334:1996;1349-1355.
38. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackner-Bernstein JD, Young ST, Holeslaw TL, Lukas MA. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation. 94:1996;2800-2806.
39. Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, Kukin MZL, Kinhal V, Udelson JE, Klapholz Gottlieb SS, Pearle D, Cody RJ, Gregory JJ, Kantrowitz NE, LeJemtel TH, Young ST, Lukas MA, Shusterman NH. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure the PRECISE Trial . Circulation. 94:1996;2793-2799.
40. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 94:1996;2807-2816.
41. Pfeffer MA, Stevenson LW. Beta-adrenergic blockers and survival in heart failure. [Editorial.] N Engl J Med. 334:1996;1396-1397.
42. Randomized, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet. 349:1997;375-380.
43. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol. 25:1995;1154-1161.
44. Packer M, Gheorghiade M, Young JB, Constantini PJ, Adams KF, Cody RJ, Smith LK, Van Voorhees L, Gourley LA, Jolly MK. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med. 329:1993;1-7.
45. Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure results of the PROVED trial . J Am Coll Cardiol. 22:1993;955-962.
46. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 336:1997;525-533.
47. Xamoterol in severe heart failure. Lancet. 336:1990;1-6.
48. Uretsky BF, Jessup M, Konstam MA, Dec GW, Leier CV, Benotti J, Murali S, Herrmann HC, Sandberg JA. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Circulation. 82:1990;774-780.
49. DiBianco R, Shabetai R, Kostuk W, Moran J, Schlant RC, Wright R. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med. 320:1989;677-683.
50. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GD, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, DeMets DL. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 325:1991;1468-1475.
51. Effect of pimobendan on exercise capacity in patients with heart failure main results from the Pimobendan in Congestive Heart Failure (PICO) trial . Heart. 76:1996;223-231.
52. Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM, Strobeck JE, Hendrix GH, Powers ER, Bain RP, White BG. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med. 329:1993;149-155.
53. Van Veldhuisen DJ, Man In't Veld AJ Dunselman PHJM, Lok DJA, Dohmen HJM, Poortermans JC, Withagen AJAM, Pasteuning WH, Brouwer J, Lie KI. Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure results of the Dutch Ibopamine Multicenter Trial (DIMT) . J Am Coll Cardiol. 22:1993;1564-1573.
54. Dohmen HJM. Efficacy and safety of Captopril and Ibopamine in mild to moderate heart failure results of the PRIME-I Study . (Abstr.) Eur Heart J. 16:1995;181.
55. Hampton JR, van Veldhuisen DJ, Kleber FX, Cowley AJ, Ardia A, Block P, Cortina A, Cserhalmi L, Follath F, Jensen G, Kayanakis J, Lie KI, Mancia G, Skene AM. Randomised study of effect of ibopamine on survival in patients with advanced heart failure. Lancet. 349:1997;971-977.
56. Elkayam U, Amin J, Mehra A, Vasquez J, Weber L, Rahimtoola SH. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation. 82:1990;1954-1961.
57. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Adverse Experience Committee, Multicenter Diltiazem Postinfarction Research Group. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation. 83:1991;52-60.
58. Packer M, Nicod P, Khandheria BR, Costello DL, Wasserman AG, Konstam MA, Weiss RJ, Moyer RR, Pinsky DJ, Abittan MH, Souhrada JF. Randomized, multicenter, double-blind, placebo-controlled evaluation of amlodipine in patients with mild-to-moderate heart failure. (Abstr.) J Am Coll Cardiol. 17:(suppl A):1991;274A.
59. Smith WB, DeAbate AC, Gollub SB, Tonkon MJ, Grossman WJ, Sharma SC, Goldenberg IF, Carley JE, Packer M. Beneficial long-term hemodynamic and clinical effects of amlodipine in chronic heart failure results of a multicenter randomized, double-blind, placebo-controlled, dose-ranging study . (Abstr.) Circulation. 90:(suppl):1994;I-603.
60. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer JH, Cropp AB, DeMets DL. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med. 335:1996;1107-1114.
61. Cohn JN, Ziesche SM, Smith R, Anand I, Dunkman B, Loeb H, Cintron G, Boden W, Baruch L, Rochin P, Loss L. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril. V-HeFT III. Circulation. 96:1997;856-863.
62. Figulla HR, Gietzen F, Zeymer U, Raiber M, Hegselmann J, Soballa R, Hilgers R. Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy. Results of the Diltiazem in Dilated Cardiomyopathy Trial. Circulation. 94:1996;346-352.
63. Levine TB. The design of the Mortality Assessment in Congestive Heart Failure Trial (MACH-1, Mibefradil) Clin Cardiol. 20:1997;320-326.
64. Echt DS, Liebson PR, Mitchell B, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL, Huther ML, Richardson DW. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 324:1991;781-788.
65. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med. 327:1992;227-233.
66. Doval HC, Nul DR, Grancelli HO, Perrone S, Bortman GR, Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet. 344:1994;493-498.
67. Nul DR, Doval HC, Grancelli HO, Varini SD, Soifer S, Perrone SV, Prieto N, Scapin O. Heart rate is a marker of amiodarone mortality reduction in severe heart failure. J Am Coll Cardiol. 29:1997;1199-1205.
68. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, Massie BM, Colling C, Lazzeri D. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med. 333:1995;77-82.
69. Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ, Simon P. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction EMIAT . Lancet. 349:1997;667-674.
70. Waldo AL, Camm AJ, deRuyter H Friedman PL, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ, Veltri EP. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet. 348:1996;7-12.
71. Bart BA, Shaw LK, McCants CB, Fortin DF, Lee KL, Califf RM, O'Connor CM. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. J Am Coll Cardiol. 30:1997;1002-1008.
72. Gheorghiade M, Bonow RO. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation (in press).
73. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, Pitt B. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation. 90:1994;2056-2069.